Study of CHIP and CCUS to track blood health changes
Part of Blood & lymphatic clinical trials.
This study follows adults who have certain blood-cell DNA changes (CHIP or CCUS) to learn how their condition may progress over time. It mainly looks at natural history—what happens in the blood without giving an active treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You can sign a written consent form.
- You have a DNA test result showing a cancer-related blood mutation (a “somatic pathogenic variant”) with at least 2% of cells affected.
- For CCUS: you must have blood count problems (low blood counts) lasting more than 30 days and at least two blood count tests done at least 3 days apart while not hospitalized.
- You must NOT have known blood cancer or most bone marrow failure conditions, and you must not be pregnant at enrollment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who may have early, unclear blood count problems or certain genetic/immune patterns that can later lead to bone marrow failure or blood cancers. It may help doctors better understand risks over time and guide earlier care.
This study looks at how certain age-related changes in blood cells (called clonal hematopoiesis) affect inflammation and health. It aims to understand why some people with these changes develop health problems like heart disease or blood disorders, while others stay healthy. Depending on your situation, you might join a group that has these changes but no health issues, or a group that has them along with specific conditions.
This trial tests an early treatment for people with a condition called high-risk CCUS, where low blood counts and gene changes raise the risk of developing blood cancer. The goal is to see if intervening early can prevent or delay progression to leukemia or MDS.
This study looks at how blood-forming stem cells change in people with clonal hematopoiesis (CHIP), a common age-related blood condition. It may help researchers understand what these changes mean and who might be at higher risk for future blood problems.
This Phase 2 study tests canakinumab to help stop high-risk clonal cytopenias of unknown significance (CCUS) from progressing into a blood cancer. If you have persistent low blood counts and specific genetic features, this treatment may lower the chance of progression.
This Phase 2 trial studies whether a statin medicine can help people with CCUS (a bone-marrow condition with abnormal genetic mutations) or lower-risk MDS (a blood disorder) that causes persistent low blood counts. It aims to see if statins can improve blood-related outcomes while keeping you safe from side effects.
Hear when a new Clonal Hematopoiesis of Indeterminate Potential trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.